Abstract 618P
Background
Vactosertib (TEW-7197), a highly selective and potent inhibitor of TGF-β receptor type 1, combined with PD-1 inhibition could induce immune restoration and enhance anti-tumor responses in patients with microsatellite stable metastatic colorectal cancer (mCRC). MP-VAC-204 is a phase 1b/2a study evaluating the combination of vactosertib with pembrolizumab in previously treated MSS mCRC. Here we report the updated safety and efficacy data of this phase 1b/2a study (NCT03724851).
Methods
Eligible patients were >18 years old with ECOG performance status 0-1 and who had disease progression after treatment with all available therapies including fluoropyrimidine and oxaliplatin or irinotecan. The MSI testing was conducted by local or central tests. Tumor biomarkers including granzyme B+ CD8+T cells were measured in serial tumor samples by multiplex immunofluorescence staining and deconvolution-based immune cell analysis. Circulating proteins, TGF-b, CTGF, PAI-1 and PDGF-AB were evaluated from serial blood samples.
Results
A total of 105 patients (36 in 200mg BID, 30 in 200mg QD, 7 in 200mg TID and 32 in 300mg BID) were enrolled. In all patients (N=105), the overall objective response rate was 13.3% [95% confidence interval (CI), 7.5- 21.4] and median duration of response was 6.0 months (95% CI, 2.9-Not Reached [NR]). Median PFS and OS were 1.3 months (95% CI, 1.2-1.4) and 15.8 months (95% CI, 7.9-NR) respectively. Overall PFS rate at 6 months was 17.1% (95% CI, 10.5-25.7) and overall survival rate at 12 months was 61.0% (95% CI, 51.0-70.3). Rash, headache and decreased appetite were the most frequent treatment emergent adverse events (TEAEs), but all were manageable. No fatal serious TEAEs were observed in any cohort. The levels of TGF-β signaling related circulating cytokines, TGF-b, CTGF, PAI-1, and PDGF-AB/BB were significantly decreased after treatment. Tumor-infiltrating and microenvironmental granzyme B secretion by CD8+ cells were significantly increased after treatment.
Conclusions
Vactosertib combined with pembrolizumab showed anti-tumor activity, prolonged overall survival and manageable safety profiles in patients with MSS mCRC. The phase 2 part is still ongoing.
Clinical trial identification
NCT03724851.
Editorial acknowledgement
We sincerely thank all patients, families, and investigators who participated in this study. The authors thank Merck & Co. staffs for supporting this study.
Legal entity responsible for the study
MedPacto.
Funding
MedPacto.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
528P - Progression risk after pregnancy in patients with glioma
Presenter: Annette Leibetseder
Session: Poster session 10
529P - Post-marketing surveillance data from patients ≥70 years of age with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy between 2011–2022
Presenter: Wenyin Shi
Session: Poster session 10
530P - Ultra low bevacizumab (BEVULTRA-100) as a novel approach in symptomatic management of high grade glioma: Can minimal dose make a difference?
Presenter: P ANURADHA
Session: Poster session 10
531P - Tumor treating fields therapy for glioblastoma: Identifying needs and satisfaction of new and long-term users
Presenter: Eleni T. Batzianouli
Session: Poster session 10
532P - Nitric oxide is a target by a combo-drug for glioblastoma treatment
Presenter: Manish Tripathi
Session: Poster session 10
533P - Oligodendrogliomas: What is the impact after the introduction of the WHO molecular classification?
Presenter: Maria Angeles Vaz Salgado
Session: Poster session 10
534P - Glioblastoma treatment in patients older than 60 years: Hypofractionated radiotherapy and temozolomide versus conventional radiotherapy and temozolomide
Presenter: Teresa Pacheco
Session: Poster session 10
535P - Hypofractionated radiotherapy in fit elderly patients with glioblastoma: Relevant or detrimental?
Presenter: Carla Martín Abreu
Session: Poster session 10
536P - Safety and efficacy of silibinin in patients with brain metastases after stereotactic radiosurgery (SRS): The SUSTAIN trial
Presenter: Niccolò Bertini
Session: Poster session 10
537P - S100A9 serum levels are associated with survival prognosis in patients with brain metastases
Presenter: Ariane Steindl
Session: Poster session 10